ANKRD33 is overexpressed in gastric adenocarcinoma and predictive for poor prognosis

References

• Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–2917.
   PubMed Web of Science ®Google Scholar
• Fock KM, Talley N, Moayyedi P, et al. Asia-Pacific consensus guidelines on gastric cancer prevention.%A Fock KM. J Gastroenterol Hepatol. 2008;23(3):351–365.
   PubMed Web of Science ®Google Scholar
• Zhou X, Yin C, Dang Y, et al. Identification of the long non-coding RNA H19 in plasma as a novel biomarker for diagnosis of gastric cancer. Sci Rep. 2015;5(1):11516.
   PubMedGoogle Scholar
• Ji Z, Wenbin L, Hongqiang C, et al. Expression of the WFDC1 gene in hepatocellular carcinoma tissues and cell lines and their prognostic values. Carcinogenesis,Teratogenesis & Mutagenesis; 2018.;30(4):291–296.
   Google Scholar
• Rikako S, Yoshihiro O, Chieko K, et al. Panky, a novel photoreceptor-specific ankyrin repeat protein, is a transcriptional cofactor that suppresses CRX-regulated photoreceptor genes. FEBS Lett. 2010;584(4):753–758.
   PubMed Web of Science ®Google Scholar
• Li J, Mahajan A, Tsai MD. Ankyrin repeat: a unique motif mediating protein-protein interactions. Biochemistry. 2006;45(51):15168–15178.
   PubMed Web of Science ®Google Scholar
• Powell JA, Gardner AE, Bais AJ, et al. Sequencing, transcript identification, and quantitative gene expression profiling in the breast cancer loss of heterozygosity region 16q24.3 reveal three potential tumor-suppressor genes. Genomics. 2002;80(3):303–310.
   PubMed Web of Science ®Google Scholar
• Neilsen PM, Cheney KM, Chia-Wei L, et al. Identification of ANKRD11 as a p53 coactivator. J Cell Sci. 2008;121(Pt 21):3541.
   PubMed Web of Science ®Google Scholar
• Bai R, Li D, Shi Z, et al. Clinical significance of Ankyrin repeat domain 12 expression in colorectal cancer. J Exp Clin Cancer Res Cr. 2013;32(1):35.
   PubMedGoogle Scholar
• Parkin DM, Bray FJ, Pisani P. Global cancer statistics, 2002. Ca A Cancer J Clin. 2005;55:74–108.
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58(2):71–96.
   PubMed Web of Science ®Google Scholar
• Ahn HS, Shin YS, Park PJ, et al. Serum biomarker panels for the diagnosis of gastric adenocarcinoma. Br J Cancer. 2012;106(4):733–739.
   PubMed Web of Science ®Google Scholar
• Reiter W, Stieber P, Reuter C, et al. Prognostic value of preoperative serum levels of CEA, CA 19-9 and CA 72-4 in gastric carcinoma. Anticancer Res. 1997;17(4B):2903–2906.
   PubMed Web of Science ®Google Scholar
• Marrelli D, Pinto E, Stefano A, et al. Clinical utility of CEA, CA 19-9, and CA 72-4 in the follow-up of patients with resectable gastric cancer. Am J Surg. 2001;181(1):16–19.
   PubMed Web of Science ®Google Scholar
• Marrelli D, Roviello F, De Stefano A, et al. Prognostic significance of CEA, CA 19-9 and CA 72-4 preoperative serum levels in gastric carcinoma. Oncology. 1999;57(1):55–62.
   PubMed Web of Science ®Google Scholar
• Gaspar MJ, Arribas I, Coca MC, et al. Prognostic value of carcinoembryonic antigen, CA 19-9 and CA 72-4 in gastric carcinoma. Tumour Biol. 2001;22(5):318–322.
   PubMedGoogle Scholar
• Ishigami S, Natsugoe S, Hokita S, et al. Clinical importance of preoperative carcinoembryonic antigen and carbohydrate antigen 19-9 levels in gastric cancer. J Clin Gastroenterol. 2001;32(1):41–44.
   PubMed Web of Science ®Google Scholar
• Juhasz M, Schulz HU, Roecken C, et al. Dual role of serum soluble E-cadherin as an indicator of metastatic development in gastric cancer. Scand J Gastroenterol. 2003;38(8):850–855.
   PubMed Web of Science ®Google Scholar
• Miki K, Morita M, Sasajima M, et al. Usefulness of gastric cancer screening using the serum pepsinogen test method. Gastric Cancer. 2006;9(4):245–253.
   PubMedGoogle Scholar
• Daryabari SS, Safaralizadeh R, Hosseinpourfeizi M, et al. Overexpression of SSH1 in gastric adenocarcinoma and its correlation with clinicopathological features. J Gastrointest Oncol. 2018;9(4):728–733.
   PubMed Web of Science ®Google Scholar
• Liu C, Li N, Lu H, et al. Circulating SFRP1 promoter methylation status in gastric adenocarcinoma and esophageal square cell carcinoma. Biomed Rep. 2015;3(1):123–127.
   PubMed Web of Science ®Google Scholar
• Zhang J, Guo L, Liu X, et al. MET overexpression, gene amplification and relevant clinicopathological features in gastric adenocarcinoma. Oncotarget. 2016;8(6):10264–10273.
   Google Scholar
• Zhang X, Peng Y, Jin Z, et al. Integrated miRNA profiling and bioinformatics analyses reveal potential causative miRNAs in gastric adenocarcinoma. Oncotarget. 2015;6(32):32878–32889.
   PubMedGoogle Scholar
• Wong KK, Engelman JA, Cantley LC. Targeting the PI3K signaling pathway in cancer. Curr Opin Genet Dev. 2010;20(1):87–90.
   PubMed Web of Science ®Google Scholar
• Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009;9(8):550–562.
   PubMed Web of Science ®Google Scholar
• Ye B, Jiang LL, Xu HT, et al. Expression of PI3K/AKT pathway in gastric cancer and its blockade suppresses tumor growth and metastasis. Int J Immunopathol Pharmacol. 2012;25(3):627–636.
   PubMed Web of Science ®Google Scholar
• Zhang H, Pan YZ, Cheung M, et al. LAMB3 mediates apoptotic, proliferative, invasive, and metastatic behaviors in pancreatic cancer by regulating the PI3K/Akt signaling pathway. Cell Death Dis. 2019;10(3):230.
   PubMedGoogle Scholar
• Xu J, Gong L, Qian Z, et al. ERBB4 promotes the proliferation of gastric cancer cells via the PI3K/Akt signaling pathway. Oncol Rep. 2018;39(6):2892–2898.
   PubMed Web of Science ®Google Scholar
• Murayama T, Inokuchi M, Takagi Y, et al. Relation between outcomes and localisation of p-mTOR expression in gastric cancer. Br J Cancer. 2009;100(5):782–788.
   PubMed Web of Science ®Google Scholar
• Tapia O, Riquelme I, Leal P, et al. The PI3K/AKT/mTOR pathway is activated in gastric cancer with potential prognostic and predictive significance. Virchows Arch. 2014;465(1):25–33.
   PubMed Web of Science ®Google Scholar
• Xiao L, Wang YC, Li WS, et al. The role of mTOR and phospho-p70S6K in pathogenesis and progression of gastric carcinomas: an immunohistochemical study on tissue microarray. J Exp Clin Cancer Res. 2009;28:152.
   PubMed Web of Science ®Google Scholar